Skip to main content Skip to search Skip to main navigation

PIC/S publishes two new documents on HBELs

On 1 June 2020, the PIC/S adopted the following two documents: 

The aim of the ten-page Aide Memoire is to assist inspectors in the inspection of health-based exposure limits (HBELs). The topics covered are HBEL assessment reports and quality risk assessment for cross-contamination control. The AiM  in a checklist format refers to the relevant sections of the GMP guidelines and to Q&A 053-1. The document is of particular interest to all manufacturers who are preparing for an inspection and need to know the requirements of the inspectors.  
The seven-page Q&A 053-1 was originally developed by the EMA and was adopted by PIC/S as a helpful document. With 13 question-answer pairs it supports the PIC/S Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (PI 046). 


Sources: 

PIC/S News  

PI 052-1 Health Based Exposure Limit Aide-Memoire.pdf 

PI 053-1 HBEL QA.pdf 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: Q&A on QP Certification Without Physical EU Import

EMA: Q&A on QP Certification Without Physical EU Import

The EMA has published a new Q&A addressing QP certification for batches that are neither manufactured within the EU/EEA nor intended for the EU/EEA market, and that are not physically imported into the EU/EEA.

Read more
EU: Agreement on the Pharmaceutical Package

EU: Agreement on the Pharmaceutical Package

On 11 December, the European Commission, the European Parliament, and the Council of the European Union reached a provisional agreement to update Europe's medicinal products regulatory framework.

Read more
EMA: Updated Q&As for Biological Medicinal Products

EMA: Updated Q&As for Biological Medicinal Products

EMA has updated its Q&A on biological medicinal products, addressing topics that previously required clarification or were subject to differing interpretation. The latest revision adds six new questions and updates several existing answers.

Read more
ICH: New Recommendations for the Manufacture of ATMPs

ICH: New Recommendations for the Manufacture of ATMPs

The ICH’s Cell and Gene Therapy Discussion Group (CGTDG), which was established in May 2023, has provided recommendations with regard to future Advanced Therapy Medicinal Products (ATMPs) Related Guidelines.

Read more
GMP Publishing Embarks on a new Digital Chapter

GMP Publishing Embarks on a new Digital Chapter

After months of intensive work, creative ideas, and technical finesse, the time has finally come: the GMP Verlag website has been given a fresh new look.
Read more
What should be considered in risk assessment?

What should be considered in risk assessment?

You can view the answer here:
Read more
Previous
Next